Literature DB >> 34165779

The combined use of endometrial ablation or resection and levonorgestrel-releasing intrauterine system in women with heavy menstrual bleeding: A systematic review.

Tamara J Oderkerk1,2, Majorie M A van de Kar1, Carlijn H M van der Zanden3, Peggy M A J Geomini1, Malou C Herman1, Marlies Y Bongers1,2.   

Abstract

INTRODUCTION: Despite the fact that endometrial ablation/resection is a very successful treatment for women with heavy menstrual bleeding, re-intervention with additional surgery is needed in 12-25% of the cases. Introducing a levonorgestrel-intrauterine system (LNG-IUS) immediately after ablation could preserve the integrity of the uterine cavity and suppress the regenerated or non-ablated endometrial tissue. Therefore, this combined treatment can perhaps lower the re-intervention rate. The aim of this systematic review was to assess the impact of the combined treatment.
MATERIAL AND METHODS: The MEDLINE, EMBASE and Cochrane library were systematically searched. No language restrictions were applied. All types of studies were included reporting on the results of endometrial ablation or resection combined with immediate insertion of LNG-IUS for treatment of heavy menstrual bleeding. The primary outcome was the number of hysterectomies after the ablation procedure. Secondary outcomes included re-intervention rates, removals of LNG-IUS, bleeding pattern, patient satisfaction, side-effects and complications. Our protocol was registered in PROSPERO, an international prospective register of systematic reviews under registration number CRD42020151384.
RESULTS: Six studies with a retrospective design and one case series with a follow up duration varying from 6 to 55 months were included. In total, 427 women were treated with the combined treatment. The studies described a lower hysterectomy and re-intervention rate after combined treatment compared to treatment with endometrial ablation/resection alone. Hysterectomy rate varied from 0-11% after combined treatment versus 9.4-24% after endometrial ablation/resection alone. Bleeding patterns and patient satisfaction appeared to be in favour of the combined treatment group. No intra or post operation complications or complications in the removal of LNG-IUS were described. Most described side effects after combined treatment were weight gain, mood changes and head-aches. An additional eleven studies with only an abstract available substantiated these findings. All the included studies had poor methodologic quality.
CONCLUSIONS: Based on the available literature inserting an LNG-IUS immediately after endometrial ablation/resection seems to lower the hysterectomy and re-intervention rates compared to ablation/resection alone. However, since only limited observational studies of low methodological quality are available, high quality research is necessary to confirm the findings of this systematic review. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  Post-Ablation Tubal Sterilization Syndrome; endometrial ablation; endometrial resection; heavy menstrual bleeding; levonorgestrel-releasing intrauterine system; menorrhagia

Year:  2021        PMID: 34165779     DOI: 10.1111/aogs.14219

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  2 in total

1.  Endometrial ablation plus levonorgestrel releasing intrauterine system versus endometrial ablation alone in women with heavy menstrual bleeding: study protocol of a multicentre randomised controlled trial; MIRA2 trial.

Authors:  Tamara J Oderkerk; Pleun Beelen; Peggy M A J Geomini; Malou C Herman; Jaklien C Leemans; Ruben G Duijnhoven; Judith E Bosmans; Justine N Pannekoek; Thomas J Clark; Ben Willem J Mol; Marlies Y Bongers
Journal:  BMC Womens Health       Date:  2022-06-27       Impact factor: 2.742

2.  LNG-IUS vs. medical treatments for women with heavy menstrual bleeding: A systematic review and meta-analysis.

Authors:  Sijing Chen; Jianhong Liu; Shiyi Peng; Ying Zheng
Journal:  Front Med (Lausanne)       Date:  2022-08-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.